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Abstract
Background: Interleukin 8 (IL-8) is a cytokine with atherogenic properties. In vitro studies
revealed that it is produced and secreted by human adipocytes. We recently reported that plasma
IL-8 is increased in obese subjects with normal glucose tolerance (NGT). The aim of the present
study was to measure plasma IL-8 concentrations in subjects with impaired glucose tolerance
(IGT).
Methods: A total of 44 subjects with marked overweight or obesity (BMI > 27.8 kg/m2), 27 with
NGT and 17 with IGT, were recruited for the present study. Plasma IL-8 levels were measured in
fasting state, after an oral glucose tolerance test (OGTT) and after euglycemic hyperinsulinemic
clamp.
Results: The studied groups did not differ in fasting IL-8 concentrations. Both OGTT and clamp
resulted in a significant increase in plasma IL-8. The change in IL-8 after clamp was similar in both
groups. In contrast, after OGTT plasma IL-8 levels (IL-8OGTT) were markedly higher in IGT
individuals. In IGT, but not NGT group, IL-8OGTT was positively related to postload glucose and
negatively to insulin sensitivity.
Conclusion: Plasma IL-8 concentrations after glucose load are increased in obese IGT subjects in
comparison to normoglycemic weight-matched individuals. Increase in plasma IL-8 might be both
insulin-mediated (during clamp) and glucose-mediated (during OGTT).
Background
Type 2 diabetes is associated with accelerated atherogene-
sis, this relationship may be observed already in the pre-
diabetic states, i.e. in impaired glucose tolerance (IGT)
[1]. Also, obesity itself is recognized as an independent
risk factor for cardiovascular disease [2]. Precise mecha-
nisms linking those conditions are not fully understood.
In recent years, theories about the role of chronic low-
grade inflammation in the pathogenesis of both type 2 di-
abetes [3] and atherosclerosis [4] have been developed.
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Interleukin-8 (IL-8) is one of the proinflammatory cy-
tokines, which might also have atherogenic properties.
Through its multiple actions, IL-8 might promote intimal
thickening and atherosclerosis. Those actions include re-
cruitment of neutrophils and T lymphocytes into the sub-
endothelial space, monocyte adhesion to endothelium
[5] and migration of vascular smooth muscle cells [6].
Macrophage-derived human foam cells contain high
amounts of IL-8 [7]. This cytokine is also able to increase
the instability of atherosclerotic plaque through inhibi-
tion of tissue inhibitor of metalloproteinase expression,
which results in the increased release of matrix-degrading
metalloproteinases [8].
Two studies of Bruun et al [9,10] reported that IL-8 is pro-
duced and secreted in vitro by human adipocytes. We re-
cently demonstrated that plasma IL-8 concentrations are
increased in obese subjects with normal glucose tolerance
(NGT) and are related to body mass index (BMI), waist-
to-hip ratio (WHR), percent body fat and fat mass and tu-
mor necrosis factor-α (TNFα) system [11]. We also ob-
served that circulating IL-8 increases both after an oral
glucose tolerance test (OGTT) and euglycemic hyperin-
sulinemic clamp. An increase after OGTT was similar in
lean and obese subjects, while after clamp it was present
only in the obese [11].
Elevated circulating IL-8 levels were also reported in type
1 and type 2 diabetic patients [12], it was hypothesized
that this cytokine could be involved in the pathogenesis of
diabetic macroangiopathy. However, no data are available
about IL-8 levels in IGT individuals.
The aim of the present study was to evaluate plasma IL-8
concentrations in obese subjects with IGT in fasting state,
after OGTT and after euglycemic hyperinsulinemic clamp.
Methods
A total of 44 subjects with marked overweight or obesity
(BMI > 27.8 kg/m2), without previously diagnosed distur-
bances of glucose tolerance, were included in the present
study. On the basis of OGTT, 27 had NGT (12 men and 15
women) and 17 had IGT (7 men and 10 women) accord-
ing to WHO criteria. Subjects with NGT were part of the
obese group reported in our previous study [11]. Basal
clinical characteristics of the studied groups are given in
Table 1. Individuals with diabetes were excluded from the
study. The participants had no cardiovascular disease, hy-
pertension, infections or any other serious medical prob-
lems. Before entering the study, physical examination and
resting electrocardiography were performed. Laboratory
analyses were performed after an overnight fast. The study
protocol was approved by the Ethics Committee of Medi-
cal Academy, Białystok. All the subjects gave written in-
formed consent before entering the study.
The BMI was calculated according to Quetelet's formula.
The waist-to-hip ratio (WHR) was estimated. The waist
circumference was measured at the smallest circumference
between the rib cage and the iliac crest, with the subject in
the standing position. The hip circumference was meas-
ured at the widest circumference between the waist and
the thighs. Percent of body fat was assessed by bioelectric
impedance analysis using the Tanita TBF-511 Body Fat
Analyzer (Tanita Corp., Tokyo, Japan), fat mass (FM) and
fat-free mass (FFM) were calculated.
Insulin sensitivity was evaluated by the euglycemic hyper-
insulinemic clamp technique as described by DeFronzo et
al [13]. On the morning of the study, two venous catheters
were inserted into antecubital veins, one for the infusion
of insulin and glucose and the other in the contralateral
hand for blood sampling, that hand was heated to approx-
imately 60°C. Insulin (Actrapid HM, Novo Nordisk, Co-
penhagen, Denmark) was given as a primed-continuous
intravenous infusion for 2 hours at 50 mU × kg-1 × h-1, re-
sulting in constant hyperinsulinemia of approximately
550 pmol/l. Arterialized blood glucose was obtained eve-
ry 5 minutes and 40% dextrose (2.22 mol/l) infusion was
adjusted to maintain plasma glucose levels at 5.0 mmol/l.
The glucose infusion rate approached stable values during
final 40 minutes of the study and the rate of whole-body
Table 1: Basal clinical characteristics of the studied groups.
NGT group (n = 27) IGT group (n = 17) p value
Age (yr) 40.89 ± 11.76 42.41 ± 5.79 0.62
BMI (kg/m2) 33.62 ± 3.19 33.93 ± 3.99 0.78
WHR 0.89 ± 0.08 0.88 ± 0.05 0.81
Percent body fat 39.98 ± 10.05 39.00 ± 6.71 0.72
FM (kg) 41.17 ± 16.79 37.02 ± 10.42 0.37
FFM (kg) 58.72 ± 7.28 56.53 ± 7.13 0.33
Data are presented as mean ± S.D. NGT, normal glucose tolerance; IGT, impaired glucose tolerance; BMI, body mass index; WHR, waist-to-hip 
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glucose uptake (M value) was calculated as the mean glu-
cose infusion rate from 80 to 120 min, corrected for glu-
cose space and normalized per kilogram of fat-free mass
(M/FFM).
Fasting blood samples were also taken from the antecu-
bital vein before the beginning of the clamp for the deter-
mination of glycated hemoglobin (HbA1c), plasma lipids
and IL-8. Plasma IL-8 concentration was also estimated at
the end (at 120 minute) of the OGTT and the clamp. For
the determination of plasma IL-8, samples were frozen at
-70°C.
Plasma glucose was measured immediately by the enzy-
matic method using glucose analyzer. Plasma insulin was
measured with the Medgenix EASIA test (BioSource Eu-
rope, Nivelles, Belgium). The minimum detectable con-
centration was 1.05 pg/l and the intra-assay and inter-
assay coefficients of variation (CVs) were below 5.5% and
10%, respectively. In this method, human and animal
proinsulins present no cross-reaction. HbA1c were meas-
ured by the high-performance liquid chromatography
method (Bio-Rad, Muenchen, Germany). Plasma total
cholesterol (TC), triglycerides (TG) and HDL-cholesterol
(HDL-C) were assessed by the enzymatic methods (Cor-
may, Warsaw, Poland). LDL-cholesterol (LDL-C) was cal-
culated with the Friedewald's formula.
Plasma IL-8 concentration was assessed with the human
ultrasensitive ELISA kit (BioSource International) with the
standard curve range of 0.39 to 25.0 pg/ml and the detec-
tion limit of the method below 100 fg/ml. The intra-assay
and inter-assay CVs were below 7.5% and 9.0%,
respectively.
The statistics were performed with the STATISTICA 5.0
program (StatSoft, Krakow, Poland). Differences between
the groups were assessed with the unpaired Student's t-
test. Differences between fasting and postload IL-8 levels
in respective groups were evaluated using the paired Stu-
dent's t-test. Relationships between variables were esti-
mated with the simple and multiple regression analysis.
The level of significance was accepted at p value less than
0.05.
Results
Subjects with IGT had higher levels of plasma glucose (p
< 0.0005) and postload insulin (p < 0.02) and lower M/
FFM value (p < 0.05) (Table 2). The difference in HbA1c
was of borderline significance (p = 0.053). Plasma lipids
did not differ between the studied groups (Table 2).
There was no significant difference in fasting IL-8 concen-
trations between NGT and IGT group (Table 3). In both
groups fasting IL-8 was related to BMI (NGT, r = 0.38, p <
0.05; IGT, r = 0.68, p < 0.005), percent body fat (NGT, r =
0.48, p < 0.02; IGT, r = 0.54, p < 0.05) and FM (NGT, r =
0.49; IGT, r = 0.62, both p < 0.01), and in NGT group also
to WHR (r = 0.46, p < 0.02). There was no significant cor-
relations between fasting IL-8 and glucose, insulin, HbA1c
and insulin sensitivity. Correlations in NGT group are
similar to those reported previously [11].
Euglycemic hyperinsulinemic clamp resulted in a signifi-
cant increase in plasma IL-8, similar in both groups (NGT,
p < 0.002; IGT, p < 0.02). IL-8 values after clamp were still
not different between the groups (Table 3). In both
groups, the change in IL-8 during clamp (∆IL8clamp) was
related to FM (NGT, r = 0.49, p < 0.01; IGT, r = 0.49, p <
0.05) and steady-state insulin concentrations (NGT, r =
0.41, p < 0.05; IGT, r = 0.57, p < 0.02).
Plasma IL-8 levels increased in both groups also after
OGTT (both p < 0.005). In that case, an increase in IL-8
Table 2: Biochemical parameters in the studied groups.
NGT group (n = 27) IGT group (n = 17) p value
Fasting glucose (mmol/l) 5.41 ± 0.49 6.10 ± 0.65 0.00027
Postload glucose (mmol/l) 6.01 ± 1.35 9.20 ± 0.89 0.000001
Fasting insulin (pmol/l) 138.37 ± 113.23 154.44 ± 38.65 0.57
Postload insulin (pmol/l) 505.79 ± 415.38 772.35 ± 198.48 0.017
HbA1c (%) 5.99 ± 0.92 6.48 ± 0.55 0.053
TC (mmol/l) 5.51 ± 1.12 5.83 ± 1.49 0.41
TG (mmol/l) 1.94 ± 1.16 2.23 ± 1.11 0.42
HDL-C (mmol/l) 1.27 ± 0.26 1.10 ± 0.44 0.18
LDL-C (mmol/l) 3.44 ± 0.97 3.71 ± 1.24 0.43
M/FFM (µmol × kg-1 × min-1) 31.62 ± 14.81 21.99 ± 8.94 0.02
Data are presented as mean ± S.D. NGT, normal glucose tolerance; IGT, impaired glucose tolerance; HbA1c, glycated hemoglobin; TC, total cho-
lesterol; TG, triglycerides; HDL-C, HDL-cholesterol; LDL-C; LDL-cholesterol; M/FFM, whole-body glucose uptake normalized for fat-free massCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/5
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(∆IL8OGTT) in IGT individuals was markedly higher than
in NGT subjects (p < 0.02). Also, IL-8 concentrations after
OGTT were markedly higher in IGT than in NGT group (p
< 0.05) (Table 3). ∆IL8OGTT was not related to insulin re-
sponse during OGTT and not to anthropometric parame-
ters in NGT and IGT subjects, while it was associated with
postload glucose in IGT (r = 0.51, p < 0.05), but not in
NGT group (r = 0.25, p = 0.21). Plasma IL-8 concentra-
tions after OGTT were positively related to postload glu-
cose level (r = 0.59, p < 0.02), and negatively to insulin
sensitivity (r=-0.49, p < 0.05) in IGT, but not in NGT
group.
Relationship between postload glucose and IL-8 values
was independent of insulin sensitivity (beta = 0.51, p <
0.02). In contrast, correlation between M/FFM and IL-8
level after OGTT was of borderline significance after ad-
justment for postload glucose (beta = -0.38, p = 0.07).
There were no differences in plasma IL-8 concentrations
in all the conditions studied between men and women in
the whole examined group and also within subgroups of
NGT and IGT individuals.
Discussion
Plasma IL-8 concentrations in the present study are simi-
lar to values found in our previous report [11] and in oth-
er observations [14].
In the present study, fasting IL-8 levels were similar in
obese subjects with NGT and IGT and were determined
mostly by body fat content and not by glucose levels.
These data indicate that similar processes are involved in
regulation of fasting plasma IL-8 levels in obese NGT and
IGT subjects. Our results suggest, that increase in plasma
IL-8 levels might be both insulin-mediated (during
clamp) and glucose-mediated (during OGTT). Acute hy-
perinsulinemia up-regulated circulating IL-8 levels in the
same manner in both groups. Our previous study revealed
that this effect of insulin is dependent on obesity [11].
It was demonstrated that glucose at high concentrations is
able to stimulate IL-8 production and secretion from cul-
tured endothelial cells [15]. Plasma IL-8 levels were in-
creased and related to the degree of metabolic control in
type 1 and type 2 diabetic subjects [12]. Recently it was re-
ported, that urinary levels of IL-8 are increased in patients
with diabetic nephropathy. Urinary IL-8 was significantly
related to HbA1c [16]. Subjects with IGT do not exhibit
prolonged overt hyperglycemia, this is the probable expla-
nation of the unchanged fasting IL-8 levels in comparison
to their weight-matched counterparts.
However, we demonstrated increased IL-8 concentrations
after oral glucose load in IGT group. Plasma IL-8 levels af-
ter OGTT were related to postload glucose concentrations.
Our previous study revealed that oral glucose load is able
to increase circulating IL-8 even in normoglycemic indi-
viduals and that this effect is probably independent of
obesity, as lean and obese subjects exhibited similar in-
crease despite different baseline IL-8 values [11]. The
present study indicates, that this effect of glucose load is
exaggerated in glucose intolerant individuals and post-
load IL-8 concentrations are increased in IGT group. Our
finding might give an additional explanation of the accel-
erated atherogenesis observed in prediabetic states.
In the previous study from our center, conducted on men
referred for coronary arteriography, a significance of post-
load glycemia as predictor for coronary atherosclerosis
was demonstrated. Marked correlation between postload
glycemia and number of involved vessels was observed in
men referred for coronary arteriography without previous-
ly known disturbances of glucose tolerance [17]. Associa-
tion of postload IL-8 and glucose values might indicate
the potential mechanism for the important role of post-
load glucose. It should be noted that this relationship is
present at glucose values higher than normal, as it was not
found in normoglycemic individuals.
Also, an inverse correlation between insulin sensitivity
and postload, but not fasting, IL-8 levels, was present only
in glucose intolerant individuals. Relationship between
IL-8 and insulin action was not reported previously. Bru-
un et al [9] observed a decrease in IL-8 adipose tissue ex-
pression after incubation with insulin sensitizing agents,
Table 3: Plasma IL-8 concentrations in the studied groups.
NGT group (n = 27) IGT group (n = 17) p value
Fasting IL-8 (pg/ml) 4.27 ± 1.61 4.22 ± 1.54 0.92
IL-8 after clamp (pg/ml) 6.23 ± 3.82 6.05 ± 3.05 0.86
IL-8 after OGTT (pg/ml) 5.02 ± 1.60 6.30 ± 2.52 0.044
Data are presented as mean ± S.D. NGT, normal glucose tolerance; IGT, impaired glucose tolerance; IL-8, interleukin 8; OGTT, oral glucose toler-
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thiazolidinedione ciglitazone and biguanide metformin.
It should be noted, that in our study the relationship be-
tween M/FFM and IL-8 level after OGTT was neither sig-
nificant in IGT subjects after controlling for postload
glucose nor it was present in NGT individuals. Also, our
results do not reveal any causality. Probably this associa-
tion might be important only in markedly insulin resist-
ant individuals, as was IGT group in the present study.
Conclusions
We conclude that plasma IL-8 concentrations after glucose
load are increased in obese IGT subjects in comparison to
normoglycemic weight-matched individuals. Our find-
ings also indicate, that an increase in plasma IL-8 might be
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